PRELUDE: ORGAN FIBROSIS-THE COMPLEX CELL BIOLOGY OF A MAJOR CLINICAL PROBLEM
In his thought-provoking review, 1 Thomas Winn called the world's attention to the underappreciated fact that E45% of all deaths in the western world can be attributed to some form of tissue or organ fibrosis. Kidney diseases signify an important set within this category, as essentially all chronic nephropathies, irrespective of their etiology, culminate in a final common pathological pathway characterized by glomerulosclerosis and/or tubulointerstitial fibrosis. 2, 3 Organ fibrosis is generally viewed as a dysregulated (and thus failed) healing process provoked by chronic or repetitive injury of the epithelium or endothelium of the affected parenchymal organs. 4 The key feature of the process is the tissue accumulation of fibroblasts and their contractile and potentially invasive subtype, the myofibroblasts (MFs), hallmarked by the expression of a-smooth muscle actin (SMA). These cell types, stimulated by a variety of fibrogenic cytokines (predominantly by transforming growth factor-b1, 5 and other humoral and mechanical inputs emanating from the injured environment [6] [7] [8] lay down an excessive amount of extracellular matrix (ECM), which ultimately leads to the destruction of the normal tissue architecture. In short, the epithelium is gradually replaced by mesenchymal cells and fibrous scar tissue. Given this scenario, it is understandable that the question of where the accumulating fibroblasts (and MFs) originate from has become a major focus in fibrosis research. Although this problem is not yet resolved, evidence has been accumulating that the sources are multiple and, depending on the organ (for example, lung, liver, lens, or kidney) and the underlying pathology, both proliferation and transformation of local cells, as well as population of the affected organ by external fibroblast progenitors may contribute to the process. 9 Accordingly, the sources may include local interstitial fibroblasts, 10 pericytes (or perivascular fibroblasts), 11, 12 local mesenchymal stem cells, bone marrow-derived-circulating fibrocytes 13 (Cd45 and collagen-1-positive cells), the endothelium, 14, 15 and last but not least, the injured epithelium itself 16, 17 In this short overview, we will concentrate on the latter mechanism, that is, on the concept that during fibrogenesis, fibroblasts can be generated from the epithelium through the process of epithelial-mesenchymal transition (EMT).
THE BIRTH OF A PARADIGM
In 1995, aiming at finding distinguishing markers for fibroblasts, Strutz et al. 18 used subtractive hybridization between murine fibroblasts and isogenic epithelium, and identified fibroblast-specific protein 1 (FSP1, also called S1004A) as one of the few gene products that was expressed in fibroblasts but not in mesangial or epithelial cells. Generation of an anti-FSP1 serum provided a powerful tool to address the origins of fibroblasts in fibrosing tissues. Using this reagent, and thereby discovering that a portion of tubular cells became FSP1 positive during immune-induced fibrogenesis, the Neilson group made an extremely careful (and pioneering) assumption: 'This pattern of anti-FSP1 staining during tissue fibrosis suggests, as a hypothesis, that fibroblasts in some cases arise, as needed, from the local conversion of epithelium'. 18 This sentence signified the birth of a new paradigm: the role of local EMT in fibrogenesis ( Figure 1 ). This concept is both powerful and intellectually appealing for two major reasons. First, it offers a direct link between the loss of epithelial functions (for example, absorption and secretion) and the gain of deleterious mesenchymal functions (enhanced ECM production). Second, it roots in and is consistent with the developmental biology of the kidney in that the tubular epithelium is a secondary epithelium, which differentiates from the metanephric mesenchyme through the process of mesenchymal-epithelial transition. 19 In this sense, the response to epithelial injury could be interpreted as the activation of a dedifferentiation program, which might either lead to healing through an epithelial-mesenchymal-epithelial cycle 20 or it might result in fibrosis through EMT. 21 
SUPPORTING FINDINGS AND EMERGING CHALLENGES
Prompted by this exciting intellectual framework, a large number of researchers set to work to establish the potential role of EMT in fibrogenesis. In the past 15 years, several hundred papers have been published, which provided observational and experimental support for the possibility that EMT is a contributor to organ fibrosis, in general, and tubulointerstitial fibrosis, in particular. (For excellent reviews, see refs 3,9,17,21-27.) These supportive arguments can be broadly classified into four categories: (1) Demonstration that tubular and other epithelial cells can indeed transform into fibroblasts and MFs when cultured and challenged in vitro. There is no doubt that epithelial cells possess this potentiality as a part of their repertoire in response to injury. (2) 28-30 'Snapshots' of molecular markers and events characteristic of EMT, as detected in tubular cells in vivo, during clinical or experimental fibrosis. These observations can be divided into two sets. The first demonstrates downregulation (partial loss) of epithelial markers (for example, E-cadherin) and concomitant upregulation of mesenchymal markers (for example, FSP1) in the injured (transitioning) epithelium. The second documents changes in the expression or activity of transcription factors, reflecting a profound transcriptional reprogramming, which is consistent with the reported transcriptional signature of EMT (see next section). (3) Fate-mapping or lineage-tracing experiments, in which the epithelium is genetically tagged, and thus cells of epithelial origin can be identified throughout the disease process. Using one version of this approach (see below) Iwano et al., 16 concluded that 36% of FSP1 þ cells (that is, fibroblasts) originated from the epithelium during unilateral ureteral obstruction (UUO) as a model of kidney fibrosis. Qualitatively similar findings were obtained in lung, [31] [32] [33] liver, 34 and intestinal models. 35 (4) Finally, recent data suggest that therapeutic approaches targeted to suppress EMT may lessen fibrosis, 36, 37 and conversely, antifibrotic interventions can mitigate the signs of EMT. [38] [39] [40] Although certainly compelling, the concept of fibrogenic EMT has been recently challenged. Although the presence and role of EMT in lung fibrosis appear to be generally accepted, 41 doubts have been raised in the context of the kidney 12, 42, 43 and the liver 44, 45 on the basis of the results of new fate-mapping experiments (Table 1 ). For example, using different epithelial and mesenchymal tags (see below), Humphreys et al. 12 found no evidence of EMT during UUO or ischemic injury, postulating that the epithelium did not give rise to any SMA þ or even FSP1 þ cells. Instead they proposed that (myo)fibroblasts were exclusively derived from local pericytes.
These opposite views have led to an ongoing debate. The arguments for and against the presence and participation of EMT have been eloquently summarized in a recent issue of JASN 46 by Michael Zeisberg and Jeremy Duffield, respectively, two excellent representatives of each opinion, whose studies had a major role in the very foundation of the differing viewpoints. Our short summary cannot and does not aspire to settle the debate or to take sides; its goal is to highlight a few facts and considerations, which may help to better define the fundamental concepts in question and to point out the strengths, as well as the potential pitfalls and limitations of each of the approaches used to address the problem. Clearly, having a meaningful debate will depend upon (1) the criteria that one uses to define EMT; (2) the particular disease entity or experimental model in which fibrosis and EMT are studied; and (3) the methods used to Fate-mapping studies have given discordant results about the presence of EMT in organ fibrosis. The discrepancies might be due to different methods to define and detect EMT in various disease models. Systematic comparisons of such variables as well as the assessment of potential differences in the background strains (a factor not easily determined in multiple transgenic animals) are warranted to establish the contribution of EMT to fibrogenesis. FSP1, fibroblast-specific protein 1; UUO, unilateral ureteral obstruction.
Kidney International (2011) 80, 41-50 detect EMT. We hope that this overview will facilitate the design of future studies and will contribute to the emergence of a balanced view, which avoids both the overestimation of the role of EMT in MF generation and the denial of the presence and importance of epithelial plasticity during fibrogenesis.
DEFINITION, TYPES MARKERS, AND CHARACTERISTICS OF EMT: LESSONS LEARNED IN VITRO AND IN VIVO
EMT is defined as a phenotypic change, characterized by the loss of apico-basal polarity, polygonal cell shape, and epithelial intercellular contacts (tight and adherens junctions), accompanied by the acquisition of elongated (mesenchymal) shape, increased motility, and contractility. 24, [47] [48] [49] The process involves dramatic remodeling of the cytoskeleton, which usually manifests as a cytokeratin-to-vimentin switch in the intermediate filaments and restructuring of microfilaments, with a loss of the junctional F-actin belt and an increase in stress fibers and/or peripheral F-actin branches. The basic theme of this profound form of epithelial plasticity can be supplemented with other attributes, such as excessive production of ECM, SMA expression, invasiveness, and reduction in apoptosis. According to the biological context in which EMT occurs as well as the presence of some specific attributes, the International EMT Association (TEMTIA) accepted the suggestion that EMT be classified into three subtypes. 23, 25, 50 Type 1 or developmental EMT occurs during embryogenesis (for example, gastrulation or neuronal crest cell formation), when primitive epithelial cells give rise to the mesenchymal cells, which in turn generate the mesendoderm. This process produces motile cells but does not involve excessive ECM deposition or intravascular invasion. During type 2 or fibrogenic EMT, secondary epithelial cells morph into fibroblasts (epithelial-fibroblast transition), which produce increased amount of ECM, and may show muscle-like characteristics. Type 3 or metastasisassociated EMT occurs when carcinoma cells turn into migrating and invasive mesenchymal cells (carcinoma-metastatic transition), which enter the bloodstream and form distant metastases in which they may revert to cancerous epithelial cells.
Type 2 EMT is associated with a plethora of changes in protein expression, 25 which predominantly affect the following functional categories: (1) constituents of the intercellular junctions, (2) molecules involved in cell-ECM interactions, (3) cytoskeletal components, and (4) the corresponding transcriptional regulators (Figure 2 ). The first set includes loss of epithelial adherens junction component E-cadherin, downregulation of tight junction constituents zonula occludens-1, occludin and various claudins, [28] [29] [30] 51, 52 and upregulation of mesenchymal junctional proteins such as N-or OB-cadherin. 53, 54 Changes related to ECM components encompass the overexpression of certain matrix proteins (for example, fibronectin and collagen I), ECM-interacting surface proteins, for example, a5 integrins 55 or the collagen receptor discoidin domain receptor-binding tyrosine kinase 2 (ref. 56) , as well as enzymes and chaperones that are involved in collagen synthesis (for example, heat shock protein 47 and prolyl 4-hydroxylase). 57 Changes in cytoskeletal elements include the abovementioned downregulation of cytokeratin and upregulation of vimentin along with the de novo expression of FSP1 and occasionally SMA. Finally, in conjunction with these responses, a multitude of transcriptional activators or repressors has been shown to exhibit characteristic changes during EMT. The best documented examples are the translocation of the adherens junction component b-catenin to the nucleus and the subsequent activation of the T-cell factor/lymphoid enhancer factorinduced transcription, 30, 32, 58, 59 which drives several mesenchymal genes; the expression of the zinc finger proteins Snail1 and Snail2, [60] [61] [62] [63] the basic helix-loop-helix factor Twist, 64, 65 and the zinc finger E-box-binding homeobox proteins ZEB1 and ZEB2, 36 which are strong repressors of E-cadherin and several tight junction components 66, 67 and can induce the expression of mesenchymal genes. 68 Another important event is the nuclear translocation of myocardinrelated transcription factor (MRTF), [69] [70] [71] an actin cytoskeleton-regulated coactivator of serum response factor, the main driver of the SMA promoter, and many other cytoskeletal genes. 72 As MRTF is translocated upon the disruption of the intercellular contacts, 69, 70 this mechanism represents a direct link between adherens junction integrity and the transcriptional reprogramming of the cytoskeleton. In addition, MRTF contributes to the downregulation of E-cadherin 63 and the expression of collagen 73 as well. Finally, recent findings suggest that the complex of CArG-box-binding factor-A and KRAB-associated protein-1 might act as a master regulator of the EMT transcriptional program. This complex binds to the cis element FTS1, which is present not only in the promoter of FSP1, but in many of the abovementioned transcriptional regulators as well, including lymphoid enhancer factor 1, Snail, and Twist. 74 Importantly, CArG-box-binding factor-A overexpression is sufficient to induce EMT, whereas inhibition of FSP1 expression is sufficient to suppress it. 75 These findings lend credence to the notion that local FSP1 expression is an indicator and accelerator of EMT.
Given this abundance of changes, the key question is: what are the real criteria of the process, that is, which changes can be taken as both necessary and sufficient requirements? It seems reasonable to suggest that detection of at least one feature within each of the four categories (contacts, ECM, cytoskeletal components, and transcription factors) should suffice. However, the detection of certain markers is by no means necessary for the declaration of EMT. For example, the expression of SMA should not be used as a criterion of EMT. This conclusion is illustrated by the fact that even in vitro, where all the above-described changes have been solidly documented, various epithelial cells lines show differing sensitivity to SMA expression. [28] [29] [30] 76 Moreover, even in susceptible epithelial lines, transforming growth factor-b1 alone is often insufficient to induce SMA expression, and a second hit, such as the disruption of the intercellular contacts 58, 77 or the concomitant activation of specific integrins, 32, 59 is a prerequisite. In any case, SMA expression is a late event that follows the loss of E-cadherin 29 and increased ECM production, and it occurs only in a subset of the transitioning epithelial cells. 58, 69 To distinguish this fullblown form of EMT, our lab (AK) used the term epithelial-MF transition or EMyT. 78 We showed that EMyT can be dissected to a fibrogenic and myogenic phase, which can be distinguished by the underlying signaling. 78 The first phase requires the presence and activation of the transforming growth factor-b effector Smad3, whereas the second phase is inhibited by Smad3, because it suppresses the activity of MRTF. Smad3 then gradually degrades, liberating the myogenic program. Although Smad3 degradation has been documented in vivo in a variety of fibrosis models [78] [79] [80] (see ref. 81 ), this process may be restricted to certain subsets of epithelial cells or other MF progenitors. This view also raises the possibility that epithelium-derived MFs (which may lack Smad3) might be quite different from MFs generated by other mechanisms, and they might not represent the most aggressive ECM-producing MF variant. On the other hand, reduced Smad3 (or in some cases Smad2. 82 ) in tubular cells may be an additional marker for the transitioning phenotype. These observations are in perfect accord with those made in the context of clinical disease and experimental models. Thus, although SMA expression has been repeatedly demonstrated in the epithelium during fibrosis (see the next section), in most cases, only a small portion (2% or less) of tubular epithelial cells has been found to stain positive for SMA, and conversely, the majority of the SMA þ cells are not localized within the tubular wall. 16, 57, 83, 84 Although in principle, this might reflect that the majority of cells with high SMA expression exhibit increased motility and have already left the tubular epithelium, the much likelier interpretation is that most SMA þ cells indeed do not derive from the tubular epithelium. In accord with this, SMA þ interstitial MFs did not seem to originate from in vivo Texas red dextran-labeled tubular cells during UUO. 85 In fact, this conclusion is consistent with all lineage-tracing experiments, as SMA has never been suggested as a sensitive marker of tubular EMT. It detects the most robust form, but the process does not have to go that far. Consequently, the absence of widespread tubular SMA expression does not mean that there is no tubular EMT. Moreover, it does not mean either that the detectable tubular SMA expression is functionally insignificant. This dramatic and possibly irreversible phenotypic change can be an important contributor to the deterioration of the tubular functions.
In conclusion, it would be worthwhile to combine the lineage-tracing experiments with the concomitant assessment of EMT in vivo, based on the four criteria discussed above.
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We propose that the loss of E-cadherin, a typical change in an EMT-related transcription factor, and the expression of FSP1 are good candidates. The first two has not been assessed, whereas FSP1 was found not to be expressed in the epithelium upon UUO in the study by Humphreys et al. 12 and Li et al. 42 As opposed to the absence of SMA, this finding is surprising and remains unexplained, given the large number of studies that documented tubular FSP1 during various forms of fibrogenesis (see next section).
Finally, it is worth addressing the overall relevance of the in vitro studies. Their obvious limitation is that although cultured cell lines and primary tubular cells can undoubtedly undergo EMT in vitro, this fact cannot prove that tubular cells do so in vivo. Nonetheless, these studies have been and remain indispensable for defining the markers of EMT, dissecting the responsible stimuli and, most importantly, identifying the underlying complex signaling and transcriptional pathways. The uncovered basic molecular mechanisms remain relevant irrespective of the major source(s) of MFs in a particular model or disease setting.
SNAPSHOTS: HOW TO CAPTURE THE ACTION
The real challenge in catching a cell in the act of EMT in vivo is that it should remain sufficiently epithelial to be recognized as such but should possess enough mesenchymal features so that it can be clearly distinguished from the normal epithelium. Owing to the transitional nature of the process, any static image at a given time provides only a snapshot. In addition, the steady-state number of the transitioning cells does not tell us the total number of cells that have been (or will be) undergoing transition. Ideally the process should be followed in real time in labeled cells when both the changes in cellular markers and the migration of the cells could be monitored. With the increasing sophistication of long-term intravital microscopy, such analysis might become available in the future. However, currently most studies have been based on the demonstration of coexistence of epithelial and mesenchymal features. Epithelial origin can be substantiated (although not quite proven) by cellular localization (that is, when cells are situated luminally to the tubular basement membrane, as long as the tubule remains an anatomically distinguishable entity) by specific external labeling of the tubular cells (for example, using lectins or the intravital probe Texas red dextran that is endocytosed specifically by tubular cells) or by detecting endogenous epithelial proteins or mRNAs using immunohistochemisty or in situ hybridization. The latter methods are also suitable to visualize mesenchymal markers. Using such colabeling/localization approaches, transitional tubular cells have been detected in a large variety of experimentally induced fibrotic conditions, including obstructive nephropathy, [86] [87] [88] [89] , chronic allograft, [97] [98] [99] and diabetic nephropathies. 100 In a thorough study, Rastaldi et al. 57 investigated 133 renal biopsies from a cohort of patients with minimal change disease, membranous nephropathy, immunoglobulin A glomerulonephritis, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, lupus nephritis, and diabetic nephrosclerosis. They used a whole array of markers, comprised of proliferation indicators; the expression of vimentin, SMA, and prolyl hydroxylase; the loss of zonula occludens-1 and cytokeratin; as well as the detection of collagen I and III protein and mRNA. They determined the number of tubular cells/high-power field that exhibited alterations in these markers and found an increase in each of the investigated EMT indicators compared with normal controls. The rarest of the tubular alterations was the expression of SMA. Importantly, they observed mesenchymal and ECM antigens, together with the loss of epithelial properties in well preserved tubular structures without basement membrane disruption, and were able to detect tubular cells that were positive for both cytokeratin and mesenchymal markers. Moreover, each marker showed significant correlation with clinical or histological parameters (for example, serum creatinine or the level of interstitial fibrosis). Taken together, a large number of studies lend firm support to the concept that in a variety of human kidney diseases, the injured epithelium shows several signs of epithelial plasticity, which are consistent with EMT. The pathogenic role of EMT in kidney fibrosis is further supported by recent findings, which indicate that interventions targeted against the EMT program exert antifibrotic effects. Members of the miR-200 family of microRNAs have been shown to mitigate EMT by inhibiting the expression of ZEB1 and ZEB2, which in turn are strong suppressors of the E-cadherin gene. Importantly, administration of miR-200b precursor suppressed the UUO-induced increase in ZEB proteins and reduced the ensuing fibrosis. 36 In summary, despite the limitations of the snapshot approach as discussed above, substantial evidence supports the claim that EMT does occur during clinical kidney disease. Although the majority of MFs may indeed originate from other sources, all viable models of the pathogenesis of kidney fibrosis should account for the dramatic changes that occur in the tubular epithelium and should explain how these alterations contribute to the progression of fibrosis.
FATE MAPPING AND LINEAGE TRACING
The ability to permanently tag cells in vivo has provided additional insights and raised further questions regarding the process of EMT. Under the control of epithelial-specific gene promoters, expression of Cre recombinase in the renal tubular cells results in genomic recombination between loxP sites, with subsequent production of a reporter protein that marks the epithelial lineage with a blue, green, or red color. [101] [102] [103] The assumption is that regardless of final phenotype if a cell was ever an epithelial cell it will carry the color marker. In theory, epithelial cells that have undergone EMT should be tagged and express the reporter gene as well as markers of fibroblast/MF lineage discussed above. This removes the need to identify or guess at the origin of the cell and it is not necessary to find an intermediate phenotype or capture a cell in the tubular lumen that is undergoing transition. A number of studies have been performed using this technique with varying and sometimes contrasting results (see Table 1 ). The original study of Neilson group 16 used the gamma GT promoter to drive Cre expression and a RosaR26 lacZ reporter mouse strain that results in tagging the proximal tubular epithelial cells. Following UUO, the authors clearly showed cells that expressed FSP1 and were positive for the lacZ gene product b-galactosidase, as visualized by an antibody against the enzyme (Figure 3) . In more recent studies, Humphreys et al. 12 used the Six2 Cre mouse line that tags all epithelial progenitors and subsequent epithelial derivatives that include epithelial cells from proximal down to the distal tubule. They also used a HoxB7 Cre mouse line that labels the collecting duct epithelium. They used a fluorescent red tag for epithelial cells and were unable to find a single cell that coexpressed the red lineage marker and FSP1, suggesting that not a single epithelial cell underwent EMT (Figure 3 ). Similar results were obtained when they used the same Cre driver with the Rosa26 lacZ reporter and visualized b-galactosidase through its enzymatic activity. Conversely, tagging cells from the Foxd1 lineage, which gives rise to stromal derivatives that likely include pericytes and peritubular fibroblasts/MFs, showed that these cells can contribute to the FSP1 þ population in fibrotic rodent models. Why are the results so different? Although it is difficult to determine without performing head-to-head experiments, there are several issues to consider. Although very informative, it must be remembered that even the most robust Cre excisors may vary in their ability to tag all cells that express Cre; even within a single mouse litter, Cre expression and efficiency of excision may vary raising the possibility that sub-populations of the 16 used the g-glutamyl transferase promoter coupled to Cre recombinase, which in turn activated the transcription of the lacZ gene (b-galactosidase) by removing a floxed stop codon from the ubiquitous Rosa26 promoter. The b-galactosidase expression (epithelial origin) was visualized by an antibody against the enzyme. Upon unilateral ureteral obstruction (UUO), they found b-galactosidase-positive cells that costained for fibroblast-specific protein 1 (FSP1; and to a much lesser extent for a-smooth muscle actin (SMA)), indicting EMT. Humphreys et al. 12 used the Six2 promoter to drive Cre, which induced the expression of red fluorescent protein (RFP) through the activation of the cytomegalovirus (CMV)-enhanced b-actin promoter. They induced UUO in these transgenic mice, and found that no red (epithelium derived) cells stained positive for FSP1 or SMA, suggesting that EMT did not take place. SMA or FSP1 positivity (green) was detected in interstitial cells. They got similar results using the same Cre driver in combination with the Rosa26 lazcZ reporter using an enzymatic assay to detect in situ b-galactosidase activity. GFP, green fluorescent protein.
epithelium may remain 'untagged'. 104 In turn, reporter genes, chosen for their ubiquitous expression, may switch 'off ' as cells differentiate or transdifferentiate. Although a lineage tag assumes that the marker is permanent, it depends upon continued transcription of the reporter gene that might become silenced. The Duffield group performed control experiments showing that in vitro (as opposed to in vivo) epithelial (that is, red) cells undergo transformation, yet they tend to keep the label (although the labeling appeared rather weak and uneven among SMA expressors). Nonetheless, this can be interpreted in two ways: SMA expression in the epithelium occurs only in vitro or the transforming epithelial cells lose the lineage tag predominantly in vivo. Further, when multiple transgenes are required as in these tagging experiments, mixed mouse strain backgrounds are often unavoidable, adding an additional variable. Finally, it is not possible to conclude that different reporters behave in a similar manner. Enzymatic reactions as required for the b-galactosidase gene in the RosaR26 line versus fluorescence in the Z/RED or Z/EG lines exhibit differences; single-cell resolution is variable, depending on the availability of robust antibodies for costaining. Cytoplasmic b-galactosidase expression as revealed by enzymatic conversion is very sensitive but tends to bleed and diffuse in tissues with higher background noise, making identification of individual cell populations within the interstitium difficult. It is noteworthy that studies supporting tubular EMT used antibody-based detection of b-galactosidase, whereas those against it used the X-gal reaction. Side-by-side comparison of the results obtained with these methods in the same system may be warranted.
There are ways to overcome some of these variables; one can design the 'best' experiment using reporters that can be detected with high-resolution antibodies at the single-cell level (green fluorescent protein is an excellent one), or isolating 'fibroblast cells' from the organ and looking for evidence of genomic rearrangement by PCR without the need to detect expression of the reporter (for example, see ref. 105 ). Thus, although lineage tracing is a powerful technique, it is not necessarily definitive, and investigators should recognize that the results are not always as black and white as they appear.
CONCLUDING REMARKS
The debate is on, and it is an exciting and intellectually productive one. In fact there are two sets of controversies. The first is intrinsic: what is the reason for the discrepancies between the studies using different fate-mapping methods in the same fibrosis model, UUO? Here, the resolution may be of technical nature, as discussed above. The second is an extrinsic one: why is it that the recent lineage-tracing studies fail to see any sign of EMT, whereas a compelling cohort of histological observations from human diseases does show signs of the process? Let us suppose that both observations are correct and valid. If so, is it possible that the chronic, more slowly-developing disease processes, in which cycles of epithelial injury and healing can alternate, are more prone to mobilize the EMT program than the rather acute and robust models (UUO, acute ischemic injury)? Can it be a question of the type and timing (kinetics) of the disease process? Could it be that in certain pathologies, the pericytes are the prime 'fibrotic responders' , whereas in others, tubular EMT might have a more significant role? To decide whether there is a discrepancy at all, fate-mapping studies should also be performed in the context of more chronic disease models. Another intriguing question arises from the experiments of Humphreys et al. 12 who showed that RFP-tagged (that is, epithelial) cells do undergo EMT and even EMyT when challenged in vitro. So why don't they do so in vivo? What is the missing triggering factor, or conversely, what anti-EMT factors are present to prevent this process? Do these factors change in time? Understanding of this difference may be highly informative. Furthermore, if pericytes are the culprit, how is the myogenic program (SMA production) mobilized in them? Do they use-as one would hypothesize-similar transcriptional reprogramming mechanisms (for example, contact-dependent MRTF translocation, Snail/ZEB/Twist activation, CArG-box-binding factor-A/KRAB-associated protein-1-mediated responses, and so on) as those described in the epithelium? What is the role of the epithelium in the activation of the other fibrogenic and myogenic cells, that is, what is the nature of epithelial-mesenchymal interactions?
With so many questions, one point remains certain: irrespective of the final outcome, the concept of fibrogenic EMT has proved to be vastly fruitful; it has opened and continues to open new avenues, as this very debate exemplifies it. It may turn out-as was often the case in the history of science-that both views hold a good chunk of the truth. The point is to keep up the inspiring discussion and the inquiry. Finally, it is important that while both sides strive to understand and conquer kidney fibrosis, the debate itself should not cause any scarring.
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